Skip to main content
Signal8
Launch Terminal

NEUROCRINE BIOSCIENCES INC (NBIX)

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Neurocrine Biosciences, Inc. logo

Neurocrine Biosciences, Inc.

NASDAQ:NBIXHealthcare
-0.19%$146.10
AH$146.10+0.00%vs close
Mkt Cap$14.85B
Float97.42M
O/S101.65M
Vol
$ Vol
RVOL
Inst Own100.6%
SI6.6%
Earnings
Dilution
Neurocrine Biosciences, Inc. logoNASDAQ:NBIX$146.10-0.19%
Phase Distribution
106 lead-sponsored trials·18 active·72 completed
Phase 130
Phase 1/21
Phase 240
Phase 328
Phase 44
Not applicable3
(7 more as collaborator)
Status Overview
Not yet recruiting2
Recruiting15
Active, not recruiting3
Completed72
Stopped13
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

    Valbenazine, Placebo oral capsule

    Tardive Dyskinesia (TD)

    Enrollment
    89
    Start
    Sep 2018
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT03698331
  • Phase 4
    Completed

    Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

    Valbenazine, Placebo oral capsule

    Tardive Dyskinesia (TD)

    Enrollment
    135
    Start
    Mar 2019
    Primary Completion
    Dec 2019
    Completion
    Jan 2020
    NCT03891862
  • Phase 4
    Completed

    Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

    Valbenazine

    Schizophrenia, Schizoaffective Disorder +3

    Enrollment
    59
    Start
    May 2023
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT05859698
  • Phase 4
    Recruiting

    A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    Valbenazine

    Schizophrenia, Schizoaffective Disorder +3

    Enrollment
    100
    Start
    Aug 2025
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2028est.
    NCT07105111
  • Phase 3
    Terminated

    Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

    Indiplon, Sertraline

    Insomnia, Depression

    Enrollment
    380
    Start
    Nov 2005
    Primary Completion
    -
    Completion
    Apr 2006
    NCT00232167
  • Phase 3
    Withdrawn

    An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

    NBI-34060

    Insomnia

    Enrollment
    0
    Start
    Sep 2007
    Primary Completion
    Jan 2008
    Completion
    Jan 2008
    NCT00525941
  • Phase 3
    Completed

    A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

    NBI-98854, Placebo

    Tardive Dyskinesia

    Enrollment
    234
    Start
    Oct 2014
    Primary Completion
    Sep 2015
    Completion
    Jul 2016
    NCT02274558
  • Phase 3
    Completed

    Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

    NBI-98854

    Tardive Dyskinesia

    Enrollment
    167
    Start
    Mar 2015
    Primary Completion
    Mar 2017
    Completion
    Mar 2017
    NCT02405091
  • Phase 3
    Completed

    Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

    Chronocort®, standard glucocorticoid therapy

    Congenital Adrenal Hyperplasia

    Enrollment
    122
    Start
    Feb 2016
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT02716818
  • Phase 3
    Completed

    Treatment of Adrenal Insufficiency in Children

    Infacort®

    Adrenal Insufficiency

    Enrollment
    24
    Start
    Mar 2015
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT02720952
  • Phase 3
    Completed

    Extension Study for Patients Entered Into Study Infacort 003

    Infacort®

    Adrenal Insufficiency

    Enrollment
    18
    Start
    Mar 2016
    Primary Completion
    Aug 2018
    Completion
    Aug 2018
    NCT02733367
  • Phase 3
    Completed

    Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

    Valbenazine

    Tardive Dyskinesia

    Enrollment
    161
    Start
    Jun 2016
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT02736955
  • Phase 3
    Completed

    A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

    Hydrocortisone

    Congenital Adrenal Hyperplasia

    Enrollment
    91
    Start
    Aug 2016
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT03062280
  • Phase 3
    Withdrawn

    Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

    Chronocort®, Standard Care

    Congenital Adrenal Hyperplasia

    Enrollment
    0
    Start
    Oct 2018
    Primary Completion
    Oct 2018
    Completion
    Jul 2021
    NCT03532022
  • Phase 3
    Completed

    Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

    Valbenazine, Placebo

    Chorea, Huntington

    Enrollment
    128
    Start
    Nov 2019
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04102579
  • Phase 3
    Completed

    Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

    Valbenazine

    Chorea, Huntington

    Enrollment
    154
    Start
    Sep 2020
    Primary Completion
    Nov 2025
    Completion
    Nov 2025
    NCT04400331
  • Phase 3
    Active, not recruiting

    Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

    Crinecerfont, Placebo

    Congenital Adrenal Hyperplasia

    Enrollment
    182
    Start
    Dec 2020
    Primary Completion
    Jul 2023
    Completion
    Aug 2027est.
    NCT04490915
  • Phase 3
    Active, not recruiting

    Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

    Crinecerfont, Placebo

    Congenital Adrenal Hyperplasia

    Enrollment
    103
    Start
    Jun 2021
    Primary Completion
    Mar 2023
    Completion
    Aug 2027est.
    NCT04806451
  • Phase 3
    Completed

    Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

    Chronocort, Cortef

    Congenital Adrenal Hyperplasia

    Enrollment
    55
    Start
    May 2022
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05063994
  • Phase 3
    Completed

    Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

    Placebo, Valbenazine

    Schizophrenia

    Enrollment
    442
    Start
    Nov 2021
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT05110157
  • Phase 3
    Completed

    Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

    Placebo, Valbenazine

    Dyskinesia, Cerebral Palsy

    Enrollment
    86
    Start
    Apr 2022
    Primary Completion
    Oct 2025
    Completion
    Mar 2026
    NCT05206513
  • Phase 3
    Terminated

    Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

    Valbenazine, Placebo

    Schizophrenia

    Enrollment
    8
    Start
    Jan 2023
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05654870
  • Phase 3
    Enrolling by invitation

    Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

    Valbenazine

    Chorea, Huntington

    Enrollment
    7
    Start
    Apr 2024
    Primary Completion
    Apr 2028est.
    Completion
    Apr 2028est.
    NCT06312189
  • Phase 3
    Recruiting

    Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    NBI-1065845, Placebo

    Major Depressive Disorder

    Enrollment
    200
    Start
    Jan 2025
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT06786624
  • Phase 3
    Recruiting

    NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    NBI-1065845, Placebo

    Major Depressive Disorder

    Enrollment
    200
    Start
    Mar 2025
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT06911112

1-25 of 106

Search ClinicalTrials.gov for “Neurocrine Biosciences”